[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658082":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":11,"studyPopulation":11,"armGroups":32,"interventions":46,"overallOfficials":63,"centralContacts":67,"locations":72,"responsibleParty":156,"collaborators":11,"id":158,"slug":159,"hasResults":160,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":11,"eligibilityCriteria":164,"healthyVolunteers":160,"sex":165,"minAge":166,"maxAge":11,"enrollmentInfo":167,"targetDuration":11,"studyType":170,"phases":171,"briefSummary":173,"conditions":174,"keywords":179,"overallStatus":181,"whyStopped":11,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":191},{"fullName":5,"class":6},"Pfizer","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Percent change from baseline in body weight",null,"Baseline, Week 32",[14,16,18,20,22,24],{"measure":15,"description":11,"timeFrame":12},"Change from baseline in body weight",{"measure":17,"description":11,"timeFrame":12},"Number of Participants With Treatment Emergent Adverse Events (TEAEs)",{"measure":19,"description":11,"timeFrame":12},"Number of Participants with Serious adverse events (SAEs)",{"measure":21,"description":11,"timeFrame":12},"Number of Participants with adverse events leading to discontinuation",{"measure":23,"description":11,"timeFrame":12},"Number of Participants with Adverse Events of Special Interest (AESIs)",{"measure":25,"description":11,"timeFrame":12},"Number of Participants with Clinical Laboratory Abnormalities",{"allocation":27,"interventionModel":28,"interventionModelDescription":11,"primaryPurpose":29,"observationalModel":11,"timePerspective":11,"maskingInfo":30},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":31,"maskingDescription":11,"whoMasked":11},"NONE",[33,40],{"label":34,"type":35,"description":36,"interventionNames":37},"Active Comparator","ACTIVE_COMPARATOR","Participants will receive Semaglutide or Tirzepatide by Subcutaneous Injection.",[38,39],"Drug: Semaglutide","Drug: Tirzepatide",{"label":41,"type":42,"description":43,"interventionNames":44},"Experimental","EXPERIMENTAL","Participants will receive Berobenatide by Subcutaneous Injection.",[45],"Drug: Berobenatide",[47,52,56],{"type":48,"name":49,"description":50,"armGroupLabels":51,"otherNames":11},"DRUG","Semaglutide","Participants will receive Semaglutide administered subcutaneously.",[34],{"type":48,"name":53,"description":54,"armGroupLabels":55,"otherNames":11},"Tirzepatide","Participants will receive Tirzepatide administered subcutaneously.",[34],{"type":48,"name":57,"description":58,"armGroupLabels":59,"otherNames":60},"Berobenatide","Participants will receive berobenatide solution for injection as subcutaneous injection.",[41],[61,62],"MET097","PF-08653944",[64],{"name":65,"affiliation":5,"role":66},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[68],{"name":65,"role":69,"phone":70,"phoneExt":11,"email":71},"CONTACT","1-800-718-1021","ClinicalTrials.gov_Inquiries@pfizer.com",[73,86,96,106,116,126,136,146],{"facility":74,"status":11,"city":75,"state":76,"zip":77,"country":78,"countryCode":79,"cosmosGeoPoint":80,"geoPoint":85,"contacts":11},"University of Alabama at Birmingham","Birmingham","Alabama","35294","United States","US",{"type":81,"coordinates":82},"Point",[83,84],-86.80249,33.52066,{"lat":84,"lon":83},{"facility":87,"status":11,"city":88,"state":89,"zip":90,"country":78,"countryCode":79,"cosmosGeoPoint":91,"geoPoint":95,"contacts":11},"Suncoast Clinical Research","New Port Richey","Florida","34652",{"type":81,"coordinates":92},[93,94],-82.71927,28.24418,{"lat":94,"lon":93},{"facility":97,"status":11,"city":98,"state":99,"zip":100,"country":78,"countryCode":79,"cosmosGeoPoint":101,"geoPoint":105,"contacts":11},"Monroe Biomedical Research","Louisville","Kentucky","40213",{"type":81,"coordinates":102},[103,104],-85.75941,38.25424,{"lat":104,"lon":103},{"facility":107,"status":11,"city":108,"state":109,"zip":110,"country":78,"countryCode":79,"cosmosGeoPoint":111,"geoPoint":115,"contacts":11},"Aa Mrc Llc","Flint","Michigan","48504",{"type":81,"coordinates":112},[113,114],-83.68746,43.01253,{"lat":114,"lon":113},{"facility":117,"status":11,"city":118,"state":119,"zip":120,"country":78,"countryCode":79,"cosmosGeoPoint":121,"geoPoint":125,"contacts":11},"Clinical Research Professionals","Chesterfield","Missouri","63005",{"type":81,"coordinates":122},[123,124],-90.57707,38.66311,{"lat":124,"lon":123},{"facility":127,"status":11,"city":128,"state":129,"zip":130,"country":78,"countryCode":79,"cosmosGeoPoint":131,"geoPoint":135,"contacts":11},"Mercury Street Medical Group, PLLC","Butte","Montana","59701",{"type":81,"coordinates":132},[133,134],-112.53474,46.00382,{"lat":134,"lon":133},{"facility":137,"status":11,"city":138,"state":139,"zip":140,"country":78,"countryCode":79,"cosmosGeoPoint":141,"geoPoint":145,"contacts":11},"Accellacare - Wilmington","Wilmington","North Carolina","28401",{"type":81,"coordinates":142},[143,144],-77.94604,34.23556,{"lat":144,"lon":143},{"facility":147,"status":11,"city":148,"state":149,"zip":150,"country":78,"countryCode":79,"cosmosGeoPoint":151,"geoPoint":155,"contacts":11},"Velocity Clinical Research, Mt. Auburn","Cincinnati","Ohio","45219",{"type":81,"coordinates":152},[153,154],-84.51439,39.12711,{"lat":154,"lon":153},{"type":157,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100658082","phase-3-a-study-to-learn-about-switching-to-a-monthly-study-medicine-called-berobenatide-pf-08653944-to-help-keep-weight-off-in-people-with-overweight-or-obesity-100658082",false,"NCT07845500","A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity","A PHASE 3 STUDY TO EVALUATE THE SWITCH TO MONTHLY BEROBENATIDE FOR MAINTAINING WEIGHT IN ADULTS WHO ARE ON WEEKLY SEMAGLUTIDE OR TIRZEPATIDE (VESPER-SWITCH)","Inclusion Criteria:\n\n* Aged ≥18 years.\n* Currently taking semaglutide or tirzepatide for obesity management.\n\nExclusion Criteria:\n\n* Diagnosis of any form of diabetes.\n* History of acute or chronic pancreatitis.\n* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN-2).","ALL","18 Years",{"count":168,"type":169},660,"ESTIMATED","INTERVENTIONAL",[172],"PHASE3","The purpose of this study is to learn about the safety and effectiveness of berobenatide in adults with overweight or obesity who have already lost weight while taking semaglutide or tirzepatide. The study does not include people with diabetes.\n\nParticipants will be in the study for about 11 months.",[175,176,177,178],"Obesity","Overweight and\u002For Obesity","Overweight","Treatment Of Obesity",[180],"nutrition disorder","NOT_YET_RECRUITING","2026-09-22",{"date":184,"type":185},"2026-09-29","ACTUAL",{"date":187,"type":169},"2026-10-01",{"date":189,"type":169},"2028-02-16",{"name":5,"class":6},8]